WCA
FOLD

Windsor Creek Advisors’s Amicus Therapeutics FOLD Stock Holding History

Windsor Creek Advisors’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-24,300
Closed -$237 – 187
2019
Q4 		$237 Buy
24,300
+5,000
+26% +$45.8K 0.06% 123
2019
Q3 		$155K Buy
+19,300
New +$209K 0.04% 143

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Windsor Creek Advisors's FOLD Position: Q1 2020 in Review

Windsor Creek Advisors sold out of Amicus Therapeutics (FOLD) in Q1 2020, closing a stake of 24,300 shares — an estimated $237 sold.

Windsor Creek Advisors first reported a position in FOLD in Q3 2019 and held it in 2 quarters. The position peaked at $155K in Q3 2019. 203 funds tracked by Wall St. Rank hold FOLD as of Q1 2020.

  • Windsor Creek Advisors reported no remaining Amicus Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Windsor Creek Advisors sold 24,300 Amicus Therapeutics shares in Q1 2020, an estimated $237.
  • Windsor Creek Advisors first reported a position in Amicus Therapeutics in Q3 2019 and held it in 2 quarters.
  • Windsor Creek Advisors's Amicus Therapeutics position peaked at $155K in Q3 2019.
  • 203 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2020.

Based on Windsor Creek Advisors's 13F filing for Q1 2020, filed 12 May 2020.